



Comparison of Adalimumab Biosimilars

Biosimilar Name	Approved Concentration	Interchangeable?	Launch Date	WAC Discount	PBM Coverage	Citrate Free?
Amjevita™ (adalimumab-atto)	Low; High concentration in development	No; Interchangeability clinical trial in progress (high concentration)	1/31/2023	5%	Same tier as Humira®: Optum Rx Express Scripts Prime Therapeutics Non-Preferred (Humira® Preferred): CVS Caremark	Yes
Unbranded adalimumab-atto				55%		
Cyltezo® (adalimumab-abdm)	Low	Yes	7/1/2023	5-7%	Same tier as Humira®: Optum Rx Express Scripts Prime Therapeutics	Yes
Hyrimoz® (adalimumab-adaz)	Low and High	No	7/1/2023	5%	Same tier as Humira®: Optum Rx Express Scripts	Low- No High- Yes
Unbranded adalimumab-adaz				81%		
Hadlima™ (adalimumab-bwwd)	Low and High	No; Interchangeability clinical trial in progress (high concentration)	7/1/2023	85%	Same Tier as Humira®: Prime Therapeutics	Low- No High- Yes
Yuflyma® (adalimumab-aaty)	High	No; Interchangeability clinical trial in progress	7/2/2023	5%		Yes
Hulio® (adalimumab-fkjp)	Low	No	7/3/2023	5%		Yes
Unbranded adalimumab-fkjp				85%		
Yusimry™ (adalimumab-aqvh)	Low; High concentration in development	No	7/3/2023	85+%	SmithRX and RxPreferred through Mark Cuban Cost Plus	Yes
Idacio® (adalimumab-aacf)	Low	No	7/3/2023	5%		Yes
Abrilada™ (adalimumab-afzb)	Low	sBLA for interchangeability pending	As early as July 2023			Yes
AVT02 (adalimumab)	High concentration aBLA pending	sBLA for interchangeability pending	After FDA approval			Yes

*Based on publicly available information